Literature DB >> 7475929

Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation.

B Burchell1, C H Brierley, D Rance.   

Abstract

Several human liver UDP-Glucuronosyltransferases (UGTs) have been cloned and the cDNAs expressed in heterologous cell lines. This technological advance has allowed the assessment of the functional substrate specificity of these UGTs. The problems which may be encountered with the latency and assay of UGTs are briefly described. The data accumulated to date indicate that the Km, and possibly the Vmax/Km, for individual substrates are the best parameters to assess the specificity of the enzymes towards xenobiotic molecules. The substrate specificity of seven UGTs has been summarised from the currently available information. Of these, UGT1*02 and UGT2B8 appear to be key isoforms in the glucuronidation of a wide range of xenobiotic substrates. Additional UGTs have yet to be identified and characterised and their future inclusion may provide further insights. Finally, the functional role of each UGT in vivo has to be determined.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7475929     DOI: 10.1016/0024-3205(95)02073-r

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  25 in total

Review 1.  Glucuronidation in humans. Pharmacogenetic and developmental aspects.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

2.  Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in Caco-2 cells--potential role in carcinogen bioinactivation.

Authors:  A Galijatovic; Y Otake; U K Walle; T Walle
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

3.  Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.

Authors:  L Iyer; C D King; P F Whitington; M D Green; S K Roy; T R Tephly; B L Coffman; M J Ratain
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

4.  Human UDP-Glucuronosyltransferases: Effects of altered expression in breast and pancreatic cancer cell lines.

Authors:  Centdrika R Dates; Tariq Fahmi; Sebastian J Pyrek; Aiwei Yao-Borengasser; Barbara Borowa-Mazgaj; Stacie M Bratton; Susan A Kadlubar; Peter I Mackenzie; Randy S Haun; Anna Radominska-Pandya
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

5.  Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.

Authors:  Terri S Armstrong; Yumei Cao; Michael E Scheurer; Elizabeth Vera-Bolaños; Rochelle Manning; Mehmet F Okcu; Melissa Bondy; Renke Zhou; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

6.  Pharmacokinetics of paracetamol and its metabolites in women at delivery and post-partum.

Authors:  Aida Kulo; Mariska Y Peeters; Karel Allegaert; Anne Smits; Jan de Hoon; Rene Verbesselt; Liesbeth Lewi; Marc van de Velde; Catherijne A J Knibbe
Journal:  Br J Clin Pharmacol       Date:  2013-03       Impact factor: 4.335

7.  Farnesol is glucuronidated in human liver, kidney and intestine in vitro, and is a novel substrate for UGT2B7 and UGT1A1.

Authors:  Adam G Staines; Pavel Sindelar; Michael W H Coughtrie; Brian Burchell
Journal:  Biochem J       Date:  2004-12-15       Impact factor: 3.857

Review 8.  Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport.

Authors:  Christina S Won; Nicholas H Oberlies; Mary F Paine
Journal:  Pharmacol Ther       Date:  2012-08-04       Impact factor: 12.310

9.  Role of atazanavir in the treatment of HIV infection.

Authors:  Pablo Rivas; Judit Morello; Carolina Garrido; Sonia Rodríguez-Nóvoa; Vincent Soriano
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

10.  Solid-phase extraction and reverse-phase HPLC: application to study the urinary excretion pattern of benzophenone-3 and its metabolite 2,4-dihydroxybenzophenone in human urine.

Authors:  Helena Gonzalez; Carl-Eric Jacobson; Ann-Marie Wennberg; Olle Larkö; Anne Farbrot
Journal:  Anal Chem Insights       Date:  2008-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.